BridgeBio Pharma stock is trading -36.77% below its average target price of $52.27 after dropping -8.8% during today's morning session. Analysts are giving the Mid-Cap Pharmaceutical company an average rating of buy and target prices ranging from $36.0 to $95.0 per share.
BridgeBio Pharma has an elevated short interest of 15.2%. The stock's short ratio, or the number of days needed for all shorts to cover their positions, is 6.67. Only 5.36% of the company's shares are owned by insiders, indicating that management does not have a deep alignment of interest with its shareholders. 94.3% of BridgeBio Pharma shares are held by institutional investors, which indicates a high level of confidence in the stock.
Institutions Invested in BridgeBio Pharma
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2024-12-31 | Kohlberg Kravis Roberts & Co. L.P. | 13% | 25,260,971 | $834,875,072 |
| 2024-12-31 | Viking Global Investors, L.P. | 13% | 25,120,991 | $830,248,733 |
| 2024-12-31 | Vanguard Group Inc | 8% | 15,077,915 | $498,325,079 |
| 2024-12-31 | Blackrock Inc. | 7% | 13,709,646 | $453,103,789 |
| 2024-12-31 | State Street Corporation | 3% | 6,182,627 | $204,335,817 |
| 2024-12-31 | Aisling Capital Management LP | 3% | 6,068,125 | $200,551,526 |
| 2024-12-31 | Janus Henderson Group PLC | 3% | 4,907,533 | $162,193,961 |
| 2024-12-31 | Farallon Capital Management LLC | 2% | 4,195,000 | $138,644,746 |
| 2024-12-31 | Frazier Life Sciences Management, L.P. | 2% | 3,800,457 | $125,605,100 |
| 2024-12-31 | Laurion Capital Management, LP | 2% | 3,740,896 | $123,636,609 |
For these reasons, we consider that the BridgeBio Pharma is the subject of mixed market sentiment.
